(Total Views: 198)
Posted On: 02/23/2017 7:56:53 PM
Post# of 106983
$AVEO breakout. upper bollie $0.81
Reverse head and shoulders.
Masdaq GM
Website
Last ten trades
80% x 100% Strong Buy
10-Q 11/4/16
low float
Shares Outstanding 75.9M
Float 62.92M
% Held by Insiders 3.79%
% Held by Institutions 30.40%
Shares Short 1.1M
Short Ratio 3.86
Short % of Float 1.96%
Shares Short (prior month) 3 1.07M
Stock technical analysis
news
and filings
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. The company?s pipeline of product candidates include Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors for renal cell carcinoma and other cancers; Ficlatuzumab, an anti-hepatocyte growth factor inhibitory antibody, which has completed Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380 Program, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia, which is a multi-factorial syndrome of involuntary weight loss associated with various cancers and diseases outside of cancer, including chronic kidney disease, congestive heart failure, and chronic obstructive pulmonary disease. It has strategic partnerships with Ophthotech Corporation; Biodesix, Inc.; St. Vincent?s Hospital Sydney Limited; Biogen Idec Inc.; and Kyowa Hakko Kirin. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Reverse head and shoulders.
Masdaq GM
Website
Last ten trades
80% x 100% Strong Buy
10-Q 11/4/16
low float
Shares Outstanding 75.9M
Float 62.92M
% Held by Insiders 3.79%
% Held by Institutions 30.40%
Shares Short 1.1M
Short Ratio 3.86
Short % of Float 1.96%
Shares Short (prior month) 3 1.07M
Stock technical analysis
news
and filings
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. The company?s pipeline of product candidates include Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors for renal cell carcinoma and other cancers; Ficlatuzumab, an anti-hepatocyte growth factor inhibitory antibody, which has completed Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380 Program, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia, which is a multi-factorial syndrome of involuntary weight loss associated with various cancers and diseases outside of cancer, including chronic kidney disease, congestive heart failure, and chronic obstructive pulmonary disease. It has strategic partnerships with Ophthotech Corporation; Biodesix, Inc.; St. Vincent?s Hospital Sydney Limited; Biogen Idec Inc.; and Kyowa Hakko Kirin. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
(0)
(0)
